Your browser doesn't support javascript.
loading
CanDriS: posterior profiling of cancer-driving sites based on two-component evolutionary model.
Zhao, Wenyi; Yang, Jingwen; Wu, Jingcheng; Cai, Guoxing; Zhang, Yao; Haltom, Jeffrey; Su, Weijia; Dong, Michael J; Chen, Shuqing; Wu, Jian; Zhou, Zhan; Gu, Xun.
Afiliação
  • Zhao W; College of Pharmaceutical Sciences & College of Computer Science and Technology, Zhejiang University, China.
  • Yang J; MOE Key Laboratory of Contemporary Anthropology, Human Phenome Institute, School of Life Sciences, Fudan University, China.
  • Wu J; College of Pharmaceutical Sciences, Zhejiang University, China.
  • Cai G; College of Pharmaceutical Sciences, Zhejiang University, China.
  • Zhang Y; College of Pharmaceutical Sciences, Zhejiang University, China.
  • Haltom J; Department of Genetics, Development and Cell Biology, Iowa State University, Ames, 12 Iowa 50011, USA.
  • Su W; Department of Genetics, Development and Cell Biology, Iowa State University, Ames, 12 Iowa 50011, USA.
  • Dong MJ; Department of Genetics, Development and Cell Biology, Iowa State University, Ames, 12 Iowa 50011, USA.
  • Chen S; College of Pharmaceutical Sciences, Zhejiang University, China.
  • Wu J; College of Computer Science and Technology & School of Medicine, Zhejiang University, China.
  • Zhou Z; College of Pharmaceutical Sciences, Innovation Institute for Artificial Intelligence in Medicine, Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare, Zhejiang University, China.
  • Gu X; Department of Genetics, Development and Cell Biology, Iowa State University, Ames, 12 Iowa 50011, USA.
Brief Bioinform ; 22(5)2021 09 02.
Article em En | MEDLINE | ID: mdl-33876217
ABSTRACT
Current cancer genomics databases have accumulated millions of somatic mutations that remain to be further explored. Due to the over-excess mutations unrelated to cancer, the great challenge is to identify somatic mutations that are cancer-driven. Under the notion that carcinogenesis is a form of somatic-cell evolution, we developed a two-component mixture model while the ground component corresponds to passenger mutations, the rapidly evolving component corresponds to driver mutations. Then, we implemented an empirical Bayesian procedure to calculate the posterior probability of a site being cancer-driven. Based on these, we developed a software CanDriS (Cancer Driver Sites) to profile the potential cancer-driving sites for thousands of tumor samples from the Cancer Genome Atlas and International Cancer Genome Consortium across tumor types and pan-cancer level. As a result, we identified that approximately 1% of the sites have posterior probabilities larger than 0.90 and listed potential cancer-wide and cancer-specific driver mutations. By comprehensively profiling all potential cancer-driving sites, CanDriS greatly enhances our ability to refine our knowledge of the genetic basis of cancer and might guide clinical medication in the upcoming era of precision medicine. The results were displayed in a database CandrisDB (http//biopharm.zju.edu.cn/candrisdb/).
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Algoritmos / Biologia Computacional / Bases de Dados Genéticas / Modelos Genéticos / Mutação / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Algoritmos / Biologia Computacional / Bases de Dados Genéticas / Modelos Genéticos / Mutação / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article